Algeta and IFE agree to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials
Algeta ASA and the Institute for Energy Technology (IFE) have agreed to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials. No financial terms are disclosed.
Alpharadin is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced prostate cancer. Its localised action helps preserve the surrounding healthy tissue thereby limiting side-effects. Bone metastases represent a major unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g. prostate, breast and lung.
The decision constitutes the first part of Algeta’s manufacturing strategy to produce and supply Alpharadin to meet expected needs of Algeta’s ongoing ALSYMPCA phase III study and planned clinical trials in other cancer indications. In addition it is planned that this expanded capacity will supply the expected commercial demand around the world following its approval and worldwide launch in collaboration with Bayer Schering Pharma AG. Under the terms of this agreement Algeta has responsibility for the manufacturing and supply of Alpharadin for commercial use.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
